News | December 18, 2008

Neoadjuvant Radiation Improves Survival in Resectable Pancreatic Cancer Patients

December 18, 2008 - Therapeutic strategies that use neoadjuvant RT for patients with resectable pancreatic cancer showed a survival benefit over surgery alone or surgery with adjuvant RT in treating pancreatic cancer, according to a study published in the November 2008 issue of the International Journal of Radiation Oncology Biology Physics.

Cancer of the exocrine pancreas is the fifth leading cause of cancer death in the U.S. Neoadjuvant chemoradiation has been investigated in several trials as a strategy for downstaging locally advanced disease to resectability.

The aim of the study was to examine the effect of neoadjuvant radiation therapy (RT) versus other treatments on long-term survival for patients with resectable pancreatic cancer in a large population-based sample group.

The Surveillance, Epidemiology and End Results (SEER) registry database (1994–2003) was queried for cases of surgically resected pancreatic cancer. Retrospective analysis was performed. The endpoint of the study was overall survival.

Using Kaplan-Meier analysis, the researchers found that the median overall survival of patients receiving neoadjuvant RT was 23 months versus 12 months with no RT and 17 months with adjuvant RT. Using Cox regression and controlling for independent covariates (age, sex, stage, grade, and year of diagnosis), the researchers found that neoadjuvant RT results in significantly higher rates of survival than other treatments (hazard ratio [HR], 0.55; 95 percent confidence interval, 0.38–0.79; p = 0.001). Specifically comparing adjuvant with neoadjuvant RT, results showed a significantly lower HR for death in patients receiving neoadjuvant RT rather than adjuvant RT (HR, 0.63; 95 percent confidence interval, 0.45–0.90; p = 0.03).

This analysis of SEER data showed a survival benefit for the use of neoadjuvant RT over surgery alone or surgery with adjuvant RT in treating pancreatic cancer. Therapeutic strategies that use neoadjuvant RT should be further explored for patients with resectable pancreatic cancer.

For more information: www.redjournal.org

Related Content

RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...